Meningococcal B vaccine may protect against gonorrhea
A collaborative study reveals that the MenB vaccine could reduce gonorrhea risk by 38% in individuals aged 14-22, offering a potential new prevention strategy amid rising antimicrobial resistance.
Findings from a collaborative study between Adelaide University and NT Health show that the meningococcal B (MenB) vaccine could lower the risk of gonorrhea in people aged 14-22.
According to an Adelaide University press release, a group of scientists linked two doses of the 4CMenB vaccine with a 38% decrease in gonorrhea risk in this population. The researchers hypothesize that this could be attributed to the vaccine initiating an immune response since gonorrhea and meningococcal disease are caused by similar bacteria.
These findings could aid prevention strategies, especially with rising rates of antimicrobial resistant strains of the disease, the release emphasized.
